• About
  • Services
  • Clients
  • Client News
  • PCG Research
  • PCG Digital
  • Contact
  • follow:

  • 6 Feb

    Coya Therapeutics Reports Statistically Significant Improvement of Inflammatory Blood Markers in Patients with Alzheimer’s Disease Following Monthly Dosing with Low-Dose IL-2, Further Supporting Clinical Development

    HOUSTON, February 06, 2025--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announced encouraging blood biomarker data from an investigator-initiated, 21-week, double-blind, placebo-controlled, exploratory Phase 2 study of LD IL-2 in patients with Alzheimer’s disease… Read More..

    Share this:
  • 6 Feb

    Aclarion Announces Northwestern Medicine as First CLARITY Trial Site

    BROOMFIELD, Colo., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced Northwestern Medicine as the initial site… Read More..

    Share this:
  • 6 Feb

    Lipella Pharmaceuticals Granted FDA Approval for Expanded Access Program for LP-310 in Oral Lichen Planus

    PITTSBURGH, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on developing innovative therapies for unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has granted approval for an Expanded Access Program (EAP) for LP-310,… Read More..

    Share this:
« Previous 1 … 33 34 35 36 37 … 245 Next »
  • Twitter feed is not available at the moment.
  • QUICK LINKS

    • About
    • Services
    • Clients
    • Client Media
    • PCG Media
    • PCG Research
    • Contact
    • Privacy Policy
    • Disclosures

    FOLLOW US

    Copyright © 2022 PCG Advisory.

    MENU logo
    • About
    • Services
    • Clients
    • Client News
    • PCG Research
    • PCG Digital
    • Contact